Cell Therapy With Treg Cells Obtained From Thymic Tissue (thyTreg) to Prevent Rejection in Heart Transplant Children

Current transplant practice is far from guaranteeing the life expectancy of patients, particularly if the patients are children. THYTECH aims to revolutionize the field of clinical immunology developing a new approach to govern the regulatory skills of immune system, preventing graft rejection and opening a new frontier in the treatment of immune diseases.

Transfer of regulatory T cells (Treg) has acquired growing interest in the race to achieve indefinite transplant survival. Up to now, the use of Treg therapy to prevent solid graft rejection in humans has demonstrated that this therapy is safe, but the clinical efficacy is limited. The small Treg numbers that can be purified from peripheral blood along with the low survival and limited suppressive capacity of differentiated Tregs obtained from adults have probably compromised the efficacy of this therapy.

The investigators have developed an innovative approach to overcome current barriers and make Treg transfer a reality equipped to achieve indefinite graft survival. The major innovation of THYTECH is the employment of thymic tissue, the site of Treg generation, as a new source of Tregs to obtain massive amounts of thymus-derived Tregs (thyTreg) with very high purity (>95% of CD 25+ Foxp3+ cells) and improved survival and suppressive capacities. The investigators are recruiting patients in a clinical trial transferring autologous Tregs in heart-transplanted children to prevent graft rejection.

Inclusion criteria

• Patient under two years of age, who meets all the necessary requirements to undergo a heart transplant.
• Patients without contraindication to immunosuppressive drugs.
• Parents and/or guardians must be willing and able to understand the purpose and risks of the study and must sign the informed consent document

Exclusion criteria

• Patients with DiGeorge Syndrome, since their thymic function is affected.
• Human immunodeficiency virus positive serology
• Epstein-Barr virus active infection
• Patients hyperimmunized with cytotoxic anti-human leukocyte antigen antibodies
• Patients with a history of previous malignancy
• Patients who have participated in other intervention studies in the last month.
• Patients who have received induction therapy with Basiliximab or Thymoglobulin.
• Patients who have previously been thymectomized or transplanted.
• Patients who have been diagnosed with severe autoimmune disease (celiac disease, autoimmune hypothyroidism, autoimmune diabetes)
• Patients who will receive an asystole heart